drugset / Trial / NCT06616922

Assessment of the Effects and Tolerability of RD03/2016 for the Treatment of Bacterial Conjunctivitis in Adults

NCT06616922

Phase 2 Completed 252 enrolled NTC srl
RandomizedParallel-groupSingle-blindTreatment

Summary

This is a phase II, randomized, parallel-group, blinded-assessor, multicentre study to assess the non-inferiority of RD03/2016 eye drops vs. levofloxacin eye drops alone (1:1) in microbiological eradication in patients with a clinical diagnosis of bacterial conjunctivitis with moderate/severe signs.

Timeline

Start
2021-11-05
Primary completion
2023-06-14
Completion
2023-09-19

Drugs

EvaluationDrugModalityDoseRoute
Subject Ketorolac Tromethamine Small molecule 0.5 % Other
Comparator Levofloxacin Small molecule 0.5 % Other